Fig. 1

The expression of the CD106 gene and protein in mesenchymal stem cells (MSCs). Comparison of cluster data between aplastic anemia (AA) patients and healthy controls (N). a Significant reduction of the mean fluorescence intensity (MFI) of CD106⁺ MSCs observed in AA patients compared to controls. b Decreased frequency of CD106⁺ MSCs shown in AA patients (n = 28) in comparison with that of healthy controls (n = 19). c The protein expression of CD106 on MSCs by Western blot from AA patients and healthy controls. d Differential expression of 15 genes between AA patients and healthy controls, CD106⁺ MSCs and CD106^– MSCs from healthy controls, and CD106⁺ MSCs and CD106^– MSCs from AA patients. e Downfold change of the CD106 gene between AA patients and healthy controls, CD106⁺ MSCs and CD106^– MSCs from healthy controls, and CD106⁺ MSCs and CD106^– MSCs from AA patients. ***P < 0.001, **** P<0.0001. CCL2 chemokine ligand 2, CXCL12 C-X-C motif chemokine 12, CSF colony-stimulating factor, CTGF connective tissue growth factor, IL interleukin, JUNB JunB proto-oncogene, EGF epidermal growth factor, PDGFA platelet-derived growth factor alpha, IGFBP5 insulin-like growth factor-binding protein 5, LEP leptin, NOG Noggin, PF4 platelet factor 4, PF4V1 platelet factor 4 variant 1